Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04819854Phase 1Completed

Single and Multiple Ascending Dose Study With EP395

Role: lead

NCT05516316Phase 1Completed

Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults

Role: lead

NCT06118684Phase 1Completed

Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin

Role: lead

NCT06677918Phase 1Completed

Clinical Trial Investigating the Effects of EP395 Following an Inhaled Endotoxin Challenge in Healthy Adults

Role: lead

NCT05572333Phase 2Completed

Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD

Role: lead

All 5 trials loaded